Ratings by Cantor Fitzgerald (Kristen Kluska)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/22/2026 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/17/2026 | DBV Technologies S.A | DBVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/16/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/15/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/15/2026 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/15/2026 | Capricor Therapeutics | CAPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/15/2026 | Eupraxia Pharmaceuticals | EPRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/7/2026 | Capricor Therapeutics | CAPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/25/2026 | Eupraxia Pharmaceuticals | EPRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/18/2026 | Atrium Therapeutics | RNA | New Coverage | Neutral (N/A) |
12.48 (12.33) |
-1.2% | Details | |
| 6/17/2026 | uniQure BV | QURE | Upgrade | Overweight (Neutral) |
26.99 (46.97) |
74.03% | Details | |
| 6/8/2026 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/21/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2026 | Esperion Therapeutics | ESPR | Downgrade | Neutral (Overweight) |
9.00 (3.18) |
-64.67% | Details | |
| 4/6/2026 | Soleno Therapeutics Inc. | SLNO | Downgrade | Neutral (Overweight) |
39.49 (53.01) |
34.24% | Details | |
| 4/1/2026 | Eupraxia Pharmaceuticals | EPRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/31/2026 | Lexeo Therapeutics | LXEO | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/30/2026 | DBV Technologies S.A | DBVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/27/2026 | DBV Technologies S.A | DBVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/26/2026 | ADMA Biologics | ADMA | Downgrade | Neutral (Overweight) |
11.33 (9.33) |
-17.65% | Details | |
| 3/25/2026 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2026 | Sarepta Therapeutics | SRPT | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/13/2026 | Capricor Therapeutics | CAPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/11/2026 | Skye Bioscience | SKYE | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/9/2026 | Cartesian Therapeutics | RNAC | Upgrade | Overweight (Neutral) |
6.85 (8.75) |
27.74% | Details | |
| 3/2/2026 | uniQure BV | QURE | Downgrade | Neutral (Overweight) |
15.63 (26.99) |
72.68% | Details | |
| 2/25/2026 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/20/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/17/2026 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Capricor Therapeutics | CAPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/15/2026 | Eupraxia Pharmaceuticals | EPRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/15/2026 | DBV Technologies S.A | DBVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/15/2026 | Abeona Therapeutics | ABEO | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/15/2026 | Skye Bioscience | SKYE | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/14/2026 | uniQure BV | QURE | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/14/2026 | Phathom Pharmaceuticals | PHAT | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/14/2026 | Capricor Therapeutics | CAPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | Lexeo Therapeutics | LXEO | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | Mereo BipPharma Group | MREO | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/9/2026 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/6/2026 | Celldex Therapeutics | CLDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/19/2025 | Amicus Therapeutics | FOLD | Downgrade | Neutral (Overweight) |
10.89 (14.49) |
33.06% | Details | |
| 12/17/2025 | DBV Technologies S.A | DBVT | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/15/2025 | DBV Technologies S.A | DBVT | New Coverage | Overweight (N/A) |
19.42 (14.06) |
-27.6% | Details | |
| 12/10/2025 | Lexeo Therapeutics | LXEO | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/1/2025 | Lexeo Therapeutics | LXEO | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/21/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/20/2025 | Lexeo Therapeutics | LXEO | New Coverage | Overweight (N/A) |
9.09 (4.91) |
-45.98% | Details | |
| 11/19/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | Eupraxia Pharmaceuticals | EPRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/12/2025 | Esperion Therapeutics | ESPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/6/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/17/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/17/2025 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/17/2025 | Esperion Therapeutics | ESPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/17/2025 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/15/2025 | Phathom Pharmaceuticals | PHAT | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/9/2025 | Phathom Pharmaceuticals | PHAT | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/6/2025 | Skye Bioscience | SKYE | Downgrade | Neutral (Overweight) |
4.75 (0.55) |
-88.42% | Details | |
| 10/3/2025 | Fulcrum Therapeutics | FULC | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/30/2025 | Eupraxia Pharmaceuticals | EPRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/30/2025 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/26/2025 | Eupraxia Pharmaceuticals | EPRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/25/2025 | uniQure BV | QURE | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/22/2025 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/22/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/22/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/22/2025 | uniQure BV | QURE | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/20/2025 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/20/2025 | Celldex Therapeutics | CLDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/19/2025 | Aquestive Therapeutics | AQST | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/19/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/30/2025 | uniQure BV | QURE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2025 | Supernus Pharmaceuticals | SUPN | Upgrade | Overweight (Neutral) |
33.41 (47.12) |
41.04% | Details | |
| 7/29/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/29/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/24/2025 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Overweight (N/A) |
5.06 (6.68) |
32.02% | Details | |
| 7/21/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/17/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/10/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/24/2025 | Capricor Therapeutics | CAPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/20/2025 | Fulcrum Therapeutics | FULC | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/17/2025 | Supernus Pharmaceuticals | SUPN | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/16/2025 | Sarepta Therapeutics | SRPT | Downgrade | Neutral (Overweight) |
36.18 (18.50) |
-48.87% | Details | |
| 6/13/2025 | Esperion Therapeutics | ESPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/13/2025 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/13/2025 | Celldex Therapeutics | CLDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/12/2025 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/6/2025 | Phathom Pharmaceuticals | PHAT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2025 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/22/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/20/2025 | Celldex Therapeutics | CLDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/14/2025 | Fulcrum Therapeutics | FULC | Upgrade | Overweight (Neutral) |
5.79 (3.71) |
-35.92% | Details | |
| 5/7/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2025 | Celldex Therapeutics | CLDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/28/2025 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/27/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/26/2025 | X4 Pharmaceuticals | XFOR | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/21/2025 | Skye Bioscience | SKYE | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/20/2025 | Capricor Therapeutics | CAPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/19/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2025 | Cartesian Therapeutics | RNAC | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/12/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2025 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2025 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/4/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2025 | ADMA Biologics | ADMA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2025 | 89bio Inc. | ETNB | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | 89bio Inc. | ETNB | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2025 | Supernus Pharmaceuticals | SUPN | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/19/2025 | Supernus Pharmaceuticals | SUPN | Downgrade | Neutral (Overweight) |
39.11 (47.12) |
20.48% | Details | |
| 2/14/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/14/2025 | Phathom Pharmaceuticals | PHAT | New Coverage | Overweight (N/A) |
5.62 (9.22) |
64.06% | Details | |
| 2/5/2025 | Skye Bioscience | SKYE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/3/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/6/2025 | Supernus Pharmaceuticals | SUPN | New Coverage | Overweight (N/A) |
36.92 (39.11) |
5.93% | Details | |
| 12/17/2024 | Aquestive Therapeutics | AQST | New Coverage | Overweight (N/A) |
3.60 (4.28) |
18.89% | Details | |
| 12/17/2024 | Esperion Therapeutics | ESPR | New Coverage | Overweight (N/A) |
2.33 (9.00) |
286.27% | Details | |
| 12/2/2024 | Cartesian Therapeutics | RNAC | New Coverage | Neutral (N/A) |
18.83 (6.85) |
-63.62% | Details | |
| 11/14/2024 | Capricor Therapeutics | CAPR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2024 | Sarepta Therapeutics | SRPT | Upgrade | Overweight (Neutral) |
125.01 (18.50) |
-85.2% | Details | |
| 9/12/2024 | Fulcrum Therapeutics | FULC | Downgrade | Neutral (Overweight) |
8.85 (3.71) |
-58.08% | Details | |
| 7/9/2024 | ADMA Biologics | ADMA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2024 | Skye Bioscience | SKYE | New Coverage | Overweight (N/A) |
11.98 (4.75) |
-60.35% | Details | |
| 5/20/2024 | Fulcrum Therapeutics | FULC | New Coverage | Overweight (N/A) |
7.55 (3.71) |
-50.86% | Details | |
| 5/15/2024 | Abeona Therapeutics | ABEO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | ADMA Biologics | ADMA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/16/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2024 | CymaBay Therapeutic | CBAY | Downgrade | Neutral (Overweight) |
25.69 (32.48) |
26.43% | Details | |
| 1/5/2024 | Capricor Therapeutics | CAPR | New Coverage | Overweight (N/A) |
5.30 (4.23) |
-20.19% | Details | |
| 11/15/2023 | Taysha Gene Therapies | TSHA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2023 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/31/2023 | Sarepta Therapeutics | SRPT | Downgrade | Neutral (Overweight) |
106.83 (125.01) |
17.02% | Details | |
| 10/5/2023 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/30/2023 | Outlook Therapeutics Incs. | OTLK | Downgrade | Neutral (Overweight) |
1.41 (0.89) |
-36.88% | Details | |
| 8/10/2023 | 89bio Inc. | ETNB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/11/2023 | Soleno Therapeutics Inc. | SLNO | New Coverage | Overweight (N/A) |
4.83 (39.49) |
717.6% | Details | |
| 6/30/2023 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/22/2023 | Humacyte | HUMA | New Coverage | Overweight (N/A) |
2.89 (0.56) |
-80.62% | Details | |
| 5/16/2023 | CymaBay Therapeutic | CBAY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2023 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2023 | Disc Medicine | IRON | New Coverage | Overweight (N/A) |
32.24 (80.26) |
148.95% | Details | |
| 4/26/2023 | Ultragenyx Pharma | RARE | New Coverage | Overweight (N/A) |
41.85 (26.45) |
-36.8% | Details | |
| 4/4/2023 | Actinium Pharma | ATNM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2023 | Galecto | GLTO | New Coverage | Overweight (N/A) |
1.76 (28.69) |
1530.11% | Details | |
| 3/16/2023 | Evelo Biosciences Inc | EVLO | Downgrade | Neutral (Overweight) |
0.31 (0.00) |
-100% | Details | |
| 2/22/2023 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2023 | Taysha Gene Therapies | TSHA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/31/2023 | CymaBay Therapeutic | CBAY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/11/2023 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/22/2022 | X4 Pharmaceuticals | XFOR | New Coverage | Overweight (N/A) |
0.80 (4.32) |
440% | Details | |
| 12/21/2022 | iBio, Inc. | IBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 11/23/2022 | uniQure BV | QURE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/23/2022 | Alpha Tau Medical Ltd. | DRTS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2022 | HTG Molecular Diagnostics | HTGM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2022 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/7/2022 | iBio, Inc. | IBIO | Upgrade | Neutral (Overweight) |
0.17 (1.40) |
723.53% | Details | |
| 9/8/2022 | Actinium Pharma | ATNM | New Coverage | Overweight (N/A) |
7.51 (0.97) |
-87.08% | Details | |
| 8/11/2022 | Abeona Therapeutics | ABEO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2022 | Galmed Pharmaceuticals | GLMD | Downgrade | Neutral (Overweight) |
0.50 (0.53) |
6% | Details | |
| 8/3/2022 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2022 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 7/5/2022 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/8/2022 | Rigel Pharmaceuticals | RIGL | Downgrade | Neutral (Overweight) |
1.76 (40.81) |
2218.75% | Details | |
| 4/14/2022 | Alpha Tau Medical Ltd. | DRTS | New Coverage | Overweight (N/A) |
10.58 (14.51) |
37.15% | Details | |
| 4/11/2022 | CymaBay Therapeutic | CBAY | New Coverage | Buy (N/A) |
3.25 (32.48) |
899.38% | Details | |
| 4/4/2022 | Sarepta Therapeutics | SRPT | New Coverage | Overweight (N/A) |
82.56 (18.50) |
-77.59% | Details | |
| 4/4/2022 | PTC Therapeutics | PTCT | New Coverage | Overweight (N/A) |
41.45 (71.84) |
73.32% | Details | |
| 3/31/2022 | Abeona Therapeutics | ABEO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/30/2022 | PolarityTE | PTE | Downgrade | Neutral (Overweight) |
0.27 (0.24) |
-11.11% | Details | |
| 2/28/2022 | Hepion Pharma | HEPA | New Coverage | Overweight (N/A) |
1.03 (0.32) |
-68.93% | Details | |
| 12/29/2021 | BioTime, Inc. | BTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2021 | CohBar | CWBR | New Coverage | Buy (N/A) |
0.65 (0.41) |
-36.92% | Details | |
| 11/9/2021 | ADMA Biologics | ADMA | New Coverage | Overweight (N/A) |
1.36 (11.33) |
733.09% | Details | |
| 10/26/2021 | 89bio Inc. | ETNB | New Coverage | Overweight (N/A) |
17.44 (14.84) |
-14.91% | Details | |
| 7/12/2021 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/30/2021 | Ocuphire | OCUP | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2021 | Evelo Biosciences Inc | EVLO | New Coverage | Overweight (N/A) |
16.08 (0.00) |
-100% | Details | |
| 5/26/2021 | Chemomab Therapeutics | CMMB | New Coverage | Overweight (N/A) |
16.07 (1.89) |
-88.24% | Details | |
| 5/19/2021 | Taysha Gene Therapies | TSHA | New Coverage | Overweight (N/A) |
21.79 (5.96) |
-72.65% | Details | |
| 5/12/2021 | Mustang Bio | MBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | Ocugen, Inc. | OCGN | Downgrade | Neutral (Overweight) |
9.58 (1.35) |
-85.91% | Details | |
| 4/14/2021 | Amicus Therapeutics | FOLD | Upgrade | Overweight (Neutral) |
9.29 (10.89) |
17.22% | Details | |
| 3/31/2021 | Lineage Cell Therapeutics Inc. | LCTX | New Coverage | Overweight (N/A) |
2.14 (1.06) |
-50.47% | Details | |
| 3/19/2021 | Marker Therapeutics | MRKR | New Coverage | Overweight (N/A) |
1.88 (1.12) |
-40.43% | Details | |
| 3/15/2021 | Ocuphire | OCUP | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2021 | Ocugen, Inc. | OCGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2021 | Heat Biologics | HTBX | New Coverage | Overweight (N/A) |
8.19 (2.83) |
-65.45% | Details | |
| 2/23/2021 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2021 | Rigel Pharmaceuticals | RIGL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2021 | Amicus Therapeutics | FOLD | Downgrade | Neutral (Overweight) |
18.73 (14.49) |
-22.64% | Details | |
| 2/3/2021 | Ocugen, Inc. | OCGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/22/2021 | iBio, Inc. | IBIO | New Coverage | Overweight (N/A) |
1.45 (0.17) |
-88.28% | Details | |
| 12/28/2020 | Amicus Therapeutics | FOLD | New Coverage | Overweight (N/A) |
24.23 (18.73) |
-22.7% | Details | |
| 12/21/2020 | uniQure BV | QURE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/1/2020 | Evogene Ltd | EVGN | New Coverage | Overweight (N/A) |
2.96 (0.67) |
-77.36% | Details | |
| 11/20/2020 | Ocuphire | OCUP | New Coverage | Overweight (N/A) |
5.52 (1.17) |
-78.8% | Details | |
| 11/19/2020 | PolarityTE | PTE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2020 | Galmed Pharmaceuticals | GLMD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2020 | Abeona Therapeutics | ABEO | Upgrade | Overweight (Neutral) |
1.07 (6.35) |
493.46% | Details | |
| 11/6/2020 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2020 | uniQure BV | QURE | New Coverage | Overweight (N/A) |
39.29 (15.63) |
-60.22% | Details | |
| 10/9/2020 | Ocugen, Inc. | OCGN | New Coverage | Overweight (N/A) |
0.33 (9.58) |
2803.03% | Details | |
| 9/28/2020 | Abeona Therapeutics | ABEO | Maintain | Neutral (N/A) |
|
Details | ||
| 8/6/2020 | PolarityTE | PTE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2020 | Taiwan Liposome Company, Ltd | TLC | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2020 | PolarityTE | PTE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/14/2020 | BiomX | PHGE | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/23/2020 | Applied Genetic Technologies Corp. | AGTC | New Coverage | Overweight (N/A) |
6.16 (0.39) |
-93.67% | Details | |
| 6/12/2020 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2020 | PolarityTE | PTE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2020 | HTG Molecular Diagnostics | HTGM | New Coverage | Overweight (N/A) |
0.40 (0.48) |
20% | Details | |
| 4/21/2020 | PolarityTE | PTE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/17/2020 | Axovant Gene Therapies | AXGT | New Coverage | Overweight (N/A) |
3.45 (2.10) |
-39.13% | Details | |
| 3/31/2020 | BiomX | PHGE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2020 | Mustang Bio | MBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2020 | Celldex Therapeutics | CLDX | New Coverage | Overweight (N/A) |
2.23 (42.92) |
1824.66% | Details | |
| 1/30/2020 | Galmed Pharmaceuticals | GLMD | New Coverage | Overweight (N/A) |
5.78 (0.53) |
-90.83% | Details | |
| 1/29/2020 | Proteostasis Therapeutics | PTI | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2020 | PolarityTE | PTE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/14/2020 | PolarityTE | PTE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2020 | BiomX | PHGE | New Coverage | Overweight (N/A) |
9.64 (0.15) |
-98.44% | Details | |
| 12/23/2019 | Taiwan Liposome Co. Ltd. | TLC | New Coverage | Overweight (N/A) |
5.70 (7.00) |
22.81% | Details | |
| 12/17/2019 | Proteostasis Therapeutics | PTI | Maintain | Overweight (N/A) |
|
Details | ||
| 12/4/2019 | Proteostasis Therapeutics | PTI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/20/2019 | Mustang Bio | MBIO | New Coverage | Overweight (N/A) |
2.57 (0.59) |
-77.04% | Details | |
| 11/15/2019 | Rigel Pharmaceuticals | RIGL | New Coverage | Overweight (N/A) |
2.29 (40.81) |
1682.1% | Details | |
| 11/11/2019 | PolarityTE | PTE | New Coverage | Overweight (N/A) |
3.31 (0.24) |
-92.75% | Details |
